Bonesupport Holding (OM:BONEX) After The FDA Delay, Is The Valuation Gap A Chance Or A Warning

FDA request reframes Bonesupport Holding stock story

Bonesupport Holding (OM:BONEX) is back in focus after the company said the FDA extended the deadline for additional CERAMENT V data, following a request for more details on previously submitted biocompatibility results.

The FDA timing news lands after a period of mixed results for Bonesupport Holding investors, with the share price at SEK227.8 and a year to date share price return of 27.98% but a 1 year total shareholder return that declined 28%. Over three and five years, total shareholder returns of 79.23% and 199.34% point to longer term momentum, with recent regulatory updates and clinical milestones continuing to shape the outlook.

Compare Bonesupport Holding's regulatory-driven story with other healthcare stocks that screen well on balance sheet strength and fundamentals in our list of solid balance sheet and fundamentals (436 results).

With Bonesupport Holding shares at SEK227.8, consensus points to a wide gap between price and fair value estimates. The stock is reported to trade at a 48% intrinsic discount and 57% below analyst targets. How much of that gap still looks justified?

Most Popular Narrative: 39.1% Undervalued

On the latest consensus view, Bonesupport Holding’s fair value of SEK373.83 sits well above the last close at SEK227.8. This frames the stock’s current debate around growth durability and regulatory progress.

The launch momentum for CERAMENT G in the U.S. is accelerating, with a trend of high repeat usage and expansion into additional indications among existing customers, which is expected to positively impact future revenue growth. The submission of the CERAMENT V application to the FDA and potential NTAP reimbursement provide future catalysts for revenue growth and improved margins once approved and implemented.

Read the complete narrative. Read the complete narrative.

Analysts are effectively sketching a playbook that leans on rapid top line growth, rising margins and a future profit multiple that needs to compress meaningfully from today’s level. Curious how those pieces fit together into a single fair value number for Bonesupport Holding? The full narrative breaks down which growth streams and profitability assumptions carry the most weight in that SEK373.83 estimate, and how the chosen discount rate shapes the gap to the current SEK227.8 share price.

Result: Fair Value of SEK373.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh risks such as currency swings pressuring margins and any setback on NTAP or broader reimbursement that could undercut the Bonesupport Holding story.

Find out about the key risks to this Bonesupport Holding narrative.

Another view on Bonesupport Holding valuation

There is a twist when looking at Bonesupport Holding through a simple earnings multiple. The stock trades on a P/E of 69.7x, which is well above the European Biotechs industry at 22.7x and above a fair ratio of 49.2x. That premium suggests real valuation risk if growth or margins slip at all.

To see what the numbers say about whether this richer P/E can hold up, take a closer look at the valuation breakdown in our fair ratio workup for Bonesupport Holding. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed tone on Bonesupport Holding so far, it makes sense to review the underlying data quickly and decide where you stand. You can then weigh that context against the 3 key rewards.

Looking for more investment ideas beyond Bonesupport Holding?

If the Bonesupport Holding story has sharpened your thinking, do not stop there. Broaden your watchlist with a few focused stock ideas built from clear fundamentals.

• Spot potential bargains early by checking stocks that combine quality fundamentals with discounted valuations using the 268 high quality undervalued stocks.
• Prioritise resilience by reviewing companies with stronger balance sheets and solid financial footing in the list of solid balance sheet and fundamentals (436 results).
• Hunt for underfollowed opportunities by scanning fundamentally robust smaller stocks in the 619 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com